Extracorporeal Pulmonary Support in Severe Pulmonary Failure in Adults
A Treatment Rediscovered
; ; ; ; ;
Background: Severe, acute respiratory failure in adults still carries a high mortality. In recent years, improved pulmonary support techniques have been used increasingly alongside conventional treatment. About 1000 such treatments are performed in Germany annually, and the number is rising rapidly. The two types of systems currently in use involve venovenous extracorporeal membrane oxygenation (ECMO) and extracorporeal carbon dioxide elimination.
Methods: The underlying principles, technical implementation, efficacy, and adverse effects of the new techniques are summarized in the light of a selective review of the literature, supplemented by the authors’ personal experience. Recommendations are given for clinical use.
Results: Currently, only limited high-quality data (from prospective randomized trials) are available to support the use of either of these techniques in adults. Veno-venous ECMO systems can effectively secure gas exchange in patients with severe respiratory failure, with experienced centers reporting survival rates from 63% to 75%. Either pump-free arteriovenous systems or low-flow ECMO systems can be used for extracorporeal carbon dioxide elimination. Complications can be serious or life-threatening and must, therefore, be rapidly recognized and treated: these include vascular injury during cannulation, venous thrombosis in a cannulated vessel, an increased hemorrhagic tendency, and thrombocytopenia.
Conclusion: Modern miniaturized pulmonary support systems enable protective mechanical ventilation with low tidal volumes, reduce ventilator-associated lung injury, and can improve survival rates in critically ill patients with a manageable adverse effect profile.
Severe acute pulmonary failure can be caused by various serious acute illnesses, such as pneumonia, aspiration, fulminant sepsis, necrotizing pancreatitis, and multiple trauma. If damage is bilateral, acute pulmonary failure is referred to internationally as acute respiratory distress syndrome (ARDS) (Box 1). Despite the capabilities of modern intensive medicine, ARDS still has a high mortality rate. A study in the USA only a few years ago found an incidence of ARDS of 58.7 cases per 100 000 people per year; the mortality rate was 41.1% (1). Severe cases, older patients, and those with concomitant illnesses exhibit a higher mortality rate, sometimes exceeding 80% (2–4). When vital gas exchange can only be ensured using aggressive, nonprotective mechanical ventilation, the prognosis worsens (2, 5) because aggressive ventilation itself leads to progressive, ventilation-induced lung injury (6).
Extracorporeal gas exchange methods for patients with severe pulmonary failure were first developed in the 1970s (7). Serious complications and severe hemorrhaging limited their use at the time; randomized trials were unable to demonstrate a survival advantage for extracorporeal membrane oxygenation (ECMO) (8, 9). Thanks to major technical developments since then, modern ECMO machines are incomparably superior to the first machines developed in the 1970s. In recent years the H1N1 influenza A pandemic has led to a rediscovery of extracorporeal pulmonary support all over the world. In Germany, venovenous (VV) ECMO has been introduced in more than 50 hospitals; interventional lung assist (iLA), a carbon dioxide removal procedure, is even more widely used.
This article provides an overview of modern extracorporeal pulmonary support systems and when their use is indicated. It analyses their clinical efficacy on the basis of our own experience and a selective search of the literature and describes the procedures’ risks and limitations.
Principle and technical implementation
Modern ECMO systems are notable for the compact design of all their individual components. The two main types are pump-driven (VV ECMO) and pumpless (iLA). For severe hypoxemic pulmonary failure, the priority is to improve oxygenation; this requires high bloodflow and therefore correspondingly large cannula diameters. For severe respiratory acidosis, when the priority is to remove carbon dioxide, lower bloodflow is sufficient; either low-flow ECMO with smaller cannulas and membrane surface areas or iLA may be used. Thus the pumpless iLA procedure is particularly suited to carbon dioxide removal, whereas VV ECMO effectively increases both oxygen transfer and carbon dioxide removal (Table).
The current standard technical equipment for VV ECMO is a centrifugal or axial pump, a plasma-resistant polymethylpentene diffusion membrane oxygenator, and antithrombotic coating for all components, usually heparin-based (Figure 1). For conventional cannulation, a long, 21–23 Fr. (French) cannula is usually implanted through the right femoral vein using the Seldinger technique, and venous blood flows through this to the oxygenator. The return line is usually the right internal jugular vein, into which a shorter, 15–19 Fr. cannula is inserted. Alternatively, a double-lumen cannula can be used instead of two separate cannulas. Double-lumen cannulas were developed for implantation into the right internal jugular vein and have the significant advantage that patients can be mobilized while receiving ECMO support. Their disadvantages are their high cost and more difficult cannulation technique. Unfractionated heparin is used as systemic anticoagulation therapy, with a target aPTT (activated partial thromboplastin time) usually 1.5 times normal value, sometimes lower for patients prone to bleeding.
In essence, iLA is an artificial arteriovenous shunt with an intercalated gas exchange module (Figure 2). Because iLA is pumpless, the driving force for bloodflow through the system is the mean arterial pressure. A femoral artery is usually used as the afferent vessel, and the contralateral femoral vein is selected as the efferent vessel. After determining the vascular cross-section using ultrasound, the Seldinger technique is used to implant the arterial cannula, the size of which is chosen in order to maintain sufficient perfusion of the leg. 15 Fr. cannulas are usually used in arteries today.
The oxygenator has a gas exchange surface area of 1.3 m2 with low flow resistance; anticoagulation with a target aPTT of around 50 seconds is usually sufficient.
Pump-driven extracorporeal membrane oxygenation
VV ECMO is usually indicated in cases of life-threatening hypoxemia (PaO2/FiO2 <80 mm Hg) despite optimized mechanical ventilation (in line with ARDSNet ) and optimum supportive treatment (negative fluid balance, prone positioning if possible). For some patients, ECMO is used as a rescue procedure, when gas exchange cannot be ensured using conventional methods and progressive hemodynamic instability develops. For other patients, essential gas exchange can only be achieved using aggressive, nonprotective ventilation (inspiratory pressure >32 cm H2O, FiO2 >0.9, tidal volume >8 mL/kg predicted body weight). Early use of extracorporeal support should be discussed in these cases, because there is a risk of further critical deterioration caused by an increase in ventilation-induced lung injury (11–13).
The main contraindications for this procedure are an untreatable underlying illness and cardiogenic shock. For the latter, venoarterial extracorporeal life support (ECLS) may be considered. When indicating ECMO, it is important to remember that it is not a causal treatment but one that temporarily stabilizes gas transfer, allows protective ventilation, and helps gain time that may be needed in order for the lungs to heal. Terminal lung disease with no prospect of lung transplantation in the near future is therefore another contraindication. A history of long-term ventilation and concomitant illnesses such as cirrhosis of the liver or chronic terminal kidney failure considerably worsen the prognosis and must also be taken into account when indicating treatment. If there are serious arguments against anticoagulation therapy, longer-term extracorporeal pulmonary support either is impossible or must be considered carefully (Box 2).
Pumpless extracorporeal support
Indications and contraindications
The indication for iLA is severe respiratory acidosis (pH <7.20) that poses a risk to vital functions and cannot be managed using conventional therapy. The system’s oxygen transfer capacity is physically limited and achieves no more than 10% to 15% of total oxygen consumption (14). Severe hypoxemia is therefore a contraindication for iLA; ECMO is indicated instead. Other contraindications are limited cardiac pump function and advanced peripheral atherosclerotic disease.
The efficacy of modern pulmonary support devices
Venovenous extracorporeal membrane oxygenation
Modern pump-driven pulmonary support methods provide highly effective extracorporeal oxygen and carbon dioxide transfer. Evaluation of our own patient data shows that beginning ECMO achieves an immediate improvement in oxygenation and resolution of hypercapnia (Figure 3). The intensiveness of ventilation can then be reduced: Tidal volume was reduced from 7.0 (6.0 to 8.4) mL/kg predicted body weight before ECMO to 4.1 (3.4 to 5.4) mL/kg on day 1 (p<0.001) (Figure 3). Peak inspiratory pressure and inspired oxygen concentration were substantially decreased within one day. In most cases, swift hemodynamic stabilization occurred at the same time.
A total of 266 adult patients (age 48 ± 17 years) with severe pulmonary failure were treated with VV ECMO at University Medical Center Regensburg between January 2006 and July 2012. Of these, 186 (70%) were successfully weaned off ECMO; 80 (30%) died during ECMO treatment, mostly as a result of multiorgan failure. Of the patients who were successfully weaned off ECMO, 28 (11%) died before being discharged from the hospital. 158 patients (59%) survived and were discharged. The average time on ECMO was 12 ± 10 days.
Mortality rates over time show a trend towards improved survival; the survival rate was 73% in 2011 (Figure 4). This is the result of increasing experience with extracorporeal pulmonary support methods. The surviving patients were younger, had lower sequential organ failure assessment (SOFA) scores, suffered from kidney failure less frequently, and had lower respiratory minute volumes before ECMO (15).
Several case series describing the outcomes of modern ECMO methods in adult patients have been published in recent years. Many centers worldwide introduced ECMO systems for cases of fulminant pulmonary failure during the H1N1 influenza A pandemic. Reported survival rates of 75% in the first publication from Australia (16) were confirmed by other centers (survival rates 68% to 71%) (17–19).
In comparison, survival rates of 52% to 63% were achieved with first-generation ECMO systems according to some publications of larger case series (more than 30 patients) (20–25). The registry of the Extracorporeal Life Support Organization (ELSO) from 1986 to 2006 (1473 patients, mean age 34 years) gives a survival rate of 50% (26).
The CESAR trial, which was published in 2009, is to date the only randomized controlled trial in adults using newer ECMO systems (27). 180 patients with severe pulmonary failure were allocated to the ECMO group or a control group that received conventional ventilation. Patients were recruited who had lung injury scores above 3.0 or uncompensated hypercapnia with pH below 7.2. The primary endpoint, death or severe disability at six months, was observed in 37% of patients in the ECMO group and 53% of patients in the control group (p = 0.03). This was the first time an advantage had been shown for ECMO treatment in adult patients. However, there were shortcomings in the design of the study: One of the criticisms made is that 22 of the 90 patients allocated to the ECMO group did not receive ECMO because they either improved swiftly or died. In addition, the patients in the control group were treated as judged best in the individual participating hospitals, and as a result only 70% of them received protective ventilation. All patients in the ECMO group were transported to Leicester, UK for treatment, leading to a bias resulting from referral to a specialized center.
Interventional lung assist
The pumpless iLA procedure is currently used in intensive medicine for patients who present severe respiratory acidosis. The largest number of cases reported on to date, 90 patients with ARDS, was published by Bein et al. in 2006 (28). iLA removed a mean of 50% of the CO2 produced, causing pH to return to normal levels swiftly. In parallel to this, a slight improvement in PaO2 was observed. The rate of survival to discharge from hospital was 41.2%. Smaller case series and case studies describe the use of iLA for brain injury (29), for status asthmaticus (30), and as bridging to lung transplantation (31). An initial prospective randomized multicenter trial (XtraVent) was recently completed. It compared conventional protective ventilation to extracorporeal carbon dioxide removal in combination with very small tidal volumes. Its results in terms of duration of ventilation and mortality rate must be awaited before iLA can be evaluated more precisely.
Adverse effects and risks
Despite size reductions and optimized design, extracorporeal pulmonary support systems remain invasive procedures with possibly life-threatening complications and are used for critically ill patients. The literature contains few reliable data on complication rates; an overview taken from the ELSO registry is reproduced in Brodie et al. (11).
Specifically, it is important to distinguish between cannula-related vascular complications and risks of ECMO that are either technical or have systemic effects on patients (Box 3).
Cannula insertion can result in vascular injuries that may cause severe bleeding, and arterial cannulation (iLA) can cause peripheral ischemia. The introduction of smaller cannulas has significantly reduced the incidence of leg ischemia, which is now around 8% (32). The frequency of venous thrombosis in the vessel into which the cannula is inserted is not known precisely; however, the risk is not inconsiderable and in our experience is more than 10%.
Technical problems observed in the past, such as plasma leakage or tube rupture, have now almost completely disappeared. For some patients, particularly those receiving longer-term treatment, the oxygenator needs to be changed as a result of progressive thrombosis. In our own patient population, this was the case in 27% of patients. If increasing hemolysis is observed, the system must be examined for complications such as partial thrombosis of the oxygenator or a thrombus in the pump head.
As a result of modern systems’ better biocompatibility, the intensiveness of systemic anticoagulation treatment can be reduced. As a result, fatal bleeding complications are very rare. Nevertheless, patients receiving ECMO are often more prone to bleeding, so individually-tailored anticoagulation must be very closely monitored. A drop in platelet count is also often seen during ECMO treatment. The extent to which heparin-induced thrombocytopenia is more frequent, and whether systemic activation of coagulation and inflammation cascades is induced, are questions currently under discussion.
The rediscovery of ECMO resulted in particular from fundamental technical developments in membrane oxygenators and pump systems and the consequent improvement in biotolerability. Thanks to this, modern systems’ efficacy and complication rates are significantly superior to those of first-generation ECMO systems. Compact design with low foreign surface areas, gas exchange fibers that cannot be penetrated by plasma, and flow-optimized blood pumps with good long-term function substantially reduce blood cell trauma, allowing long-term use of ECMO for several weeks.
Modern oxygenators have excellent gas transfer, so patients’ oxygenation can be ensured quickly. At the same time, carbon dioxide is removed effectively, making it possible to reduce the respiratory minute ventilation of patients’ native lungs immediately. With a bloodflow of 2.8 L/min ECMO accounts for more than 50% of oxygen consumption and approximately two-thirds of carbon dioxide removal (33). If necessary, ECMO can supply a higher proportion of required oxygen, more than 80%, using a higher bloodflow, although this may be accompanied by more complications.
Extracorporeal pulmonary support techniques are some of the treatment options available for severe pulmonary failure in specialized centers. While on the one hand the procedure’s efficacy in gas transfer is well documented, on the other hand it is important never to forget that it can cause potentially serious complications. Technical or clinical problems may be acutely life-threatening, so experience and interdisciplinary collaboration are essential. In Germany, more than 50 hospitals have formed an ARDS network in order to optimize ARDS treatment together and facilitate access to information on up-to-date availability of ECMO treatment places online (34) (in German).
Scientific literature on the use of modern pulmonary support systems for adults does not yet provide sufficient information to assess their value with certainty. Only one randomized trial has been published; there are no Cochrane reviews on the subject. Although the CESAR trial showed better survival with no severe disability in the ECMO group (27), its results have been questioned, as is discussed above. Another randomized trial (the EOLIA trial) was recently begun in France. In 2011 a British matched-pair analysis was published showing that ECMO halved the mortality rate for severe H1N1 influenza A infection (23.7% versus 52.5%) (19). In this case, too, patients were transported to specialized centers. This shows that for critically unstable patients an ECMO system should be implanted in the referring hospital by an experienced mobile team (>100 patients in our own patient population), if this is necessary to ensure patients are fit for transport.
Extracorporeal techniques are increasingly used in intensive care medicine to treat hypercapnic pulmonary failure. iLA is currently the most popular procedure in Germany. Low-flow VV ECMO systems with smaller cannulas and gas exchange modules are becoming established as an alternative. For selected patient groups with high mortality risk following intubation, extracorporeal procedures are used on an individual basis to avoid invasive ventilation (35–37). There is no evidence as yet that extracorporeal carbon dioxide removal improves survival rates or reduces the duration of ventilation.
VV ECMO can swiftly ensure gas transfer in patients suffering from severe pulmonary failure with life-threatening hypoxia. Protective ventilation with small tidal volumes, reduced ventilation pressure and adapted inspired oxygen concentration made possible by the use of ECMO is of great importance. This can limit ventilation-induced lung injury and have a positive effect on patient survival.
We would like to thank all employees of University Medical Center Regensburg who work with extracorporeal pulmonary support procedures in both scientific work and everyday clinical practice.
Special thanks are due to Dr. Matthias Lubnow, PD Dr. Christian Karagiannidis, Dr. Matthias Amann, Dr. Dirk Lunz, PD Dr. Daniele Camboni, Prof. Michael Hilker, and Prof. Michael Pfeifer for their efforts in the transport and treatment of critically ill patients receiving ECMO.
Conflict of interest statement
PD Dr. Müller has received reimbursement of travel expenses and lecture fees from Maquet Cardiopulmonary, Rastatt, Germany.
Prof. Bein has received fees for consultancy on the Advisory Board and lecture fees from Novalung, Heilbronn, Germany.
Mr. Philipp has received fees for consultancy on the Advisory Board from Maquet Cardiopulmonary, Rastatt, Germany.
Prof. Schmid has received reimbursement of conference fees and travel expenses, lecture fees, and funding for studies (third-party funding) from Maquet Cardiopulmonary, Rastatt, Germany.
The other authors declare that no conflict of interest exists.
Manuscript received on 20 August 2012, revised version accepted on
20 December 2012.
Translated from the original German by Caroline Devitt, M.A.
PD Dr. med. Thomas Müller
Department of Internal Medicine II
University Medical Center Regensburg
Franz-Josef-Strauss Allee 11
93053 Regensburg, Germany
Department of Internal Medicine II: PD Dr. med. Müller, Prof. Dr. med. Riegger
Department of Anaesthesia: Prof. Dr. med. Bein, Prof. Dr. med. Graf
Department of Cardiothoracic Surgery: Philipp, Prof. Dr. med. Schmid
* PD Dr. med. Müller and Prof. Dr. med. Bein have equally contributed to the manuscript.
|1.||Rubenfeld GD, Caldwell E, Peabody E, et al.: Incidence and outcomes of acute lung injury. N Engl J Med 2005; 353: 1685–93. CrossRef MEDLINE|
|2.||Villar J, Perez-Mendez L, Basaldua S, et al.: Age, plateau pressure and PaO2/FiO2 at ARDS onset predict outcome. Respir Care 2011; 56: 420–8. CrossRef MEDLINE|
|3.||Eachempati SR, Hydo LJ, Shou J, Barie PS: Outcomes of acute respiratory distress syndrome (ARDS) in elderly patients. J Trauma 2007; 63: 344–50. CrossRef MEDLINE|
|4.||Vasilyev S, Schaap RN, Mortensen JD: Hospital survival rates of patients with acute respiratory failure in modern respiratory intensive care units: an international, multicenter, prospective survey. Chest 1995; 107: 1083–8. CrossRef MEDLINE|
|5.||Ferguson ND, Frutos-Vivar F, Esteban A, et al. for the Mechanical Ventilation International Group. Airway pressure, tidal volumes, and mortality in patients with acute respiratory distress syndrome. Crit Care Med 2005; 33: 21–30. CrossRef MEDLINE|
|6.||Plakati M, Hubmayr RD: The physical basis of ventilator-induced lung injury. Expert Rev Respir Med 2010; 4: 373–85. CrossRef MEDLINE PubMed Central|
|7.||Hill JD, O´Brien TG, Murray JJ, et al.: Prolonged extracorporeal oxygenation for acute post-traumatic respiratory failure (shock-lung syndrome). Use of the Bramson membrane lung. |
N Engl J Med 1972; 286: 629–34. CrossRef MEDLINE
|8.||Zapol WM, Snider MT, Hill JD, et al.: Extracorporeal membrane oxygenation in severe respiratory failure. A randomised prospective study. JAMA 1979; 242: 2193–6. CrossRef MEDLINE|
|9.||Morris AH, Fallace CJ, Menlove RL, et al.: Randomized clinical trial of pressure-controlled inverse ratio ventilation and extracorporeal CO2 removal for adult respiratory distress syndrome. Am J Respir Crit Care Med 1994; 149: 295–305. MEDLINE|
|10.||The Acute Respiratory Distress Syndrome Network: Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. N Engl J Med 2000; 342: 1301–8. CrossRef MEDLINE|
|11.||Brodie D, Bacchetta M: Extracorporeal membrane oxygenation for ARDS in adults. N Engl J Med 2011; 365: 1905–14. CrossRef MEDLINE|
|12.||Combes A, Bacchetta M, Brodie D, Müller T, Pellegrino V: Extracorporeal membrane oxygenation for respiratory failure in adults. Curr Opin Crit Care 2012; 18: 99–104. CrossRef MEDLINE|
|13.||Extracorporeal Life Support Organization: Guidelines. www.elsonet.org/index.php/resources/guidelines.html (last accessed on 20 January 2013).|
|14.||Müller T, Lubnow M, Philipp A, et al.: Extracorporeal pumpless interventional lung assist in clinical practice: determinants of efficacy. Eur Respir J 2009; 33: 551–8. CrossRef MEDLINE|
|15.||Schmid C, Philipp A, Hilker M, et al.: Veno-venous extracorporeal membrane oxygenation for acute lung failure in adults. J Heart Lung Transpl 2012; 31: 9–15. CrossRef MEDLINE|
|16.||Australia and New Zealand Extracorporeal Membrane Oxygenation (ANZ ECMO) Influenza Investiagtors, Davies A, Jones D, Bailey M, et al.: Extracorporeal membrane oxygenation for 2009 influenza A(H1N1) acute respiratory distress syndrome. JAMA 2009; 302: 1888–95. CrossRef MEDLINE|
|17.||Extracorporeal Life Support Organization: H1N1 Registry. www.elsonet.org/index.php/registry/h1n1-registry.html (last accessed on 20 January 2013)|
|18.||Patroniti N, Zangrillo A, Pappalardo F, et al.: The Italian ECMO network experience during the 2009 influenza A (H1N1) pandemic: preparation for severe respiratory emergency outbreaks. Intensive Care Med 2011; 37: 1447–57. CrossRef MEDLINE|
|19.||Noah MA, Peek GJ, Finney SJ, et al.: Referral to an extracorporeal membrane oxygenation center and mortality among patients with severe 2009 influenza A (H1N1). JAMA 2011; 306: 1659–68. CrossRef MEDLINE|
|20.||Gattinoni L, Pesenti A, Mascheroni D, et al.: Low-frequency positive-pressure ventilation with extracorporeal CO2 removal in severe acute respiratory failure. JAMA 1986; 256: 881–6. CrossRef MEDLINE|
|21.||Hemmila MR, Rowe SA, Boules TN, et al.: Extracorporeal life support for severe acute respiratory distress syndrome in adults. Ann Surg 2004; 240: 595–607. MEDLINE PubMed Central|
|22.||Peek GJ, Moore HM, Moore N, Sosnowski AW, Firmin RK: Extracorporeal membrane oxygenation for adult respiratory failure. Chest 1997; 112: 759–64. CrossRef MEDLINE|
|23.||Lewandowski K, Roissaint R, Pappert D, Gerlach H, Slama KJ, Weidemann H: High survival rate in 122 ARDS patients managed according to a clinical algorithm including extracorporeal membrane oxygenation. Intensive Care Med 1997; 23: 819–35. CrossRef MEDLINE|
|24.||Mols G, Loop T, Geiger K, Farthmann E, Benzing A: Extracorporeal membrane oxygenation: a ten-year experience. Am J Surg 2000; 180: 144–54. CrossRef MEDLINE|
|25.||Beiderlinden M, Eikermann M, Boes T, Breitfeld C, Peters J: Treatment of severe acute respiratory distress syndrome: role of extracorporeal gas exchange. Intensive Care Med 2006; 32: 1627–31. CrossRef MEDLINE|
|26.||Brogan TV, Thiagarajan RR, Rycus PT, Bartlett RH, Bratton SL: Extracorporeal membrane oxygenation in adults with severe respiratory failure: a multi-center database. Intensive Care Med 2009; 35: 2105–14. CrossRef MEDLINE|
|27.||Peek GJ, Mugford M, Tiruvoipati R, et al.: Efficacy and economic assessment of conventional ventilatory support versus extracorporeal membrane oxygenation for severe adult respiratory failure (CESAR): a multicentre randomised controlled trial. Lancet 2009; 374: 1351–63. CrossRef MEDLINE|
|28.||Bein T, Weber F, Philipp A, et al.: A new pumpless extracorporeal interventional lung assist in critical hypoxemia/hypercapnia. Crit Care Med 2006; 34: 1372–7. CrossRef MEDLINE|
|29.||Bein T, Scherer MN, Philipp A, Weber F, Woertgen C: Pumpless extracorporeal lung assist (pECLA) in patients with acute respiratory distress syndrome and severe brain injury. J Trauma 2005; 58: 1294–7. CrossRef MEDLINE|
|30.||Elliot SC, Paramasivam K, Oram J, Bodenham AR, Howell SJ, Mallick A: Pumpless extracorporeal carbon dioxide removal for life-threatening asthma. Crit Care Med 2007; 35: 945–8. CrossRef MEDLINE|
|31.||Fischer F, Simon AR, Welte T, et al.: Bridge to lung transplantation with the novel pumpless interventional lung assist device NovaLung. J Thorac Cardiovasc Surg 2006; 131: 719–23. CrossRef MEDLINE|
|32.||Zimmermann M, Bein T, Arlt M, et al.: Pumpless extracorporeal interventional lung assist in patients with acute respiratory distress syndrome: a prospective pilot study. Crit Care 2009; 13: R10. CrossRef MEDLINE PubMed Central|
|33.||Müller T, Philipp A, Luchner A, et al.: A new miniaturized system for extracorporeal membrane oxygenation in adult respiratory failure. Crit Care 2009; 13: R205. CrossRef MEDLINE PubMed Central|
|34.||ARDS Netzwerk Deutschland. Freie Kapazitäten. www.ARDSnetwork.de/Kapazitäten im Netzwerk.html (last accessed on 20 January 2013)|
|35.||Kluge S, Braune SA, Engel M, et al.: Avoiding invasive mechanical ventilation by extracorporeal carbon dioxide removal in patients failing noninvasive ventilation. Intensive Care Med 2012; 38: 1632–9. CrossRef MEDLINE|
|36.||Fuehner T, Kuehn C, Hadem J, et al.: Extracorporeal membrane oxygenation in awake patients as bridge to lung transplantation. Am J Respir Crit Care Med 2012; 185: 763–8. CrossRef MEDLINE|
|37.||Wiesner O, Hadem J, Sommer W, et al.: Extracorporeal membrane oxygenation in a nonintubated patient with acute respiratory distress syndrome. Eur Respir J 2012; 40: 1296–8. CrossRef MEDLINE|
|38.||Bernard GR, Artigas A, Brigham KL, et al.: The American-European Consensus Conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordination. Am J Respir Crit Care Med 1994; 149: 818–24. MEDLINE|
|39.||The ARDS Definition Task Force: Acute respiratory distress syndrome. The Berlin Definition. JAMA 2012; 307: 2526–33. MEDLINE|